Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | SDHA | P31040 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CALML3 | P27482 | 1/20 | 0.60 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204305 | 0.92 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5240102 | 0.92 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL23833823 | 0.91 | F10 (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27252753 | 0.90 | F10 (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL23847765 | 0.90 | F10 (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18410708 | 0.90 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL22698503 | 0.89 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3207960 | 0.88 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8308403 | 0.88 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3207948 | 0.88 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795601-B2 | Compositions and methods for cancer treatment | BIOVISTA, INC. (US) | 2017-10-24 | — | — | US | claimed |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2013-10-03 | — | — | US | claimed |
| US-6989381-B2 | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | PHARMACIA CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| EP-1311296-B1 | SOLUTION OF AN OXAZOLIDINONE ANTIBIOTIC DRUG | PHARMACIA CORP (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1294717-B1 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UPJOHN CO LLC (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040191326-A1 | Taste-masking vehicle for coated oxazolidinone particles | REO JOSEPH P (US) | 2004-09-30 | — | — | US | claimed |
| EP-1406880-A1 | CRYSTALLINE THIAZINE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | claimed |
| US-6696426-B2 | SUITABLE FOR TOPICAL ADMINISTRATION TO EYE FOR THERAPY OR PROPHYLAXIS OF EYE INFECTIONS DUE TO GRAM POSITIVE BACTERIA | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | claimed |
| US-20040019012-A1 | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | claimed |
| US-20030232089-A1 | Ophthalmic formulation with novel gum composition | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | claimed |
| US-6551584-B2 | Oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment or prophylaxis of a grampositive bacterial infection of an eye | PHARMACIA & UPJOHN COMPANY | 2003-04-22 | — | — | US | claimed |
| EP-1294717-A2 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| US-20030027790-A1 | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems | PHARMACIA CORPORATION | 2003-02-06 | — | — | US | claimed |
| WO-2003006441-A1 | CRYSTALLINE THIAZINE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | claimed |
| US-20030008012-A1 | Composition for rectal delivery of an oxazolidinone antibacterial drug | PHARMACIA & UPJOHN COMPANY | 2003-01-09 | — | — | US | claimed |
| US-20020156072-A1 | Thiazine oxazolidinone | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020068720-A1 | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | PHARMACIA CORPORATION | 2002-06-06 | — | — | US | claimed |
| WO-2002030395-A1 | TOPICAL ANTIBIOTIC COMPOSITION FOR TREATMENT OF EYE INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2001098297-A2 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UP JOHN COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232089-A1 | Ophthalmic formulation with novel gum composition | PDE6C, PDE6A, PDE6H | MAOA 1312/4885MAOB 1165/4885PTGS1 696/4885 |
| US-20020156072-A1 | Thiazine oxazolidinone | OXA1L, TLR5, TALDO1 | MAOA 2596/4885MAOB 2433/4885PTGS1 3145/4885 |
| US-20040191326-A1 | Taste-masking vehicle for coated oxazolidinone particles | SORD, OXA1L, TAS2R20 | MAOA 3161/4885MAOB 3076/4885PTGS1 4613/4885 |
| US-20030027790-A1 | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems | PDCD2L, TBCD, OXA1L | MAOA 4089/4885MAOB 4340/4885PTGS1 3102/4885 |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BRAF, ERBB3, ERBB2 | MAOA 554/4885MAOB 219/4885PTGS1 2512/4885 |
| US-20030008012-A1 | Composition for rectal delivery of an oxazolidinone antibacterial drug | MSH2, MCRS1, CUTA | MAOA 187/4885MAOB 1770/4885PTGS1 3483/4885 |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | CUTA, DEK, LPXN | MAOA 1172/4885MAOB 1818/4885PTGS1 2187/4885 |
| US-20040019012-A1 | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride | PDCD2L, DSC1, TBCD | MAOA 3992/4885MAOB 4044/4885PTGS1 4292/4885 |
| US-20020068720-A1 | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | ABCB11, SLC47A1, TBCD | MAOA 3908/4885MAOB 3598/4885PTGS1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.